Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Guardian Capital LP

Guardian Capital LP grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 10.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 211,452 shares of the company’s stock after purchasing an additional 20,586 shares during the period. Guardian Capital LP’s holdings in Novo Nordisk A/S were worth $18,189,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Rehmann Capital Advisory Group boosted its stake in shares of Novo Nordisk A/S by 3.0% during the fourth quarter. Rehmann Capital Advisory Group now owns 14,260 shares of the company’s stock worth $1,227,000 after buying an additional 415 shares during the period. AQR Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 0.7% during the fourth quarter. AQR Capital Management LLC now owns 51,341 shares of the company’s stock valued at $4,416,000 after acquiring an additional 353 shares during the last quarter. Northern Trust Corp lifted its position in Novo Nordisk A/S by 26.8% during the fourth quarter. Northern Trust Corp now owns 4,689,098 shares of the company’s stock worth $403,356,000 after buying an additional 991,022 shares during the period. Shorepoint Capital Partners LLC raised its holdings in shares of Novo Nordisk A/S by 0.6% in the 4th quarter. Shorepoint Capital Partners LLC now owns 71,245 shares of the company’s stock worth $6,128,000 after purchasing an additional 454 shares during the period. Finally, Tri Locum Partners LP raised its holdings in shares of Novo Nordisk A/S by 212.2% in the 4th quarter. Tri Locum Partners LP now owns 209,984 shares of the company’s stock worth $18,063,000 after purchasing an additional 142,727 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 4.0 %

NVO stock opened at $65.12 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company’s 50-day simple moving average is $72.84 and its 200 day simple moving average is $88.85. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The company has a market capitalization of $292.23 billion, a PE ratio of 19.79, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.54%.

Analyst Ratings Changes

A number of brokerages have weighed in on NVO. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an “underperform” rating for the company. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. BMO Capital Markets restated a “market perform” rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.